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 To Viljam 
 
 ”Livet har ett värde 
 endast genom sitt innehåll för andra” 
  
 Dag Hammarskjöld 
  
 ABSTRACT 
 
Biochemical biomarkers are small molecular species, naturally varying or experimentally 
induced, which are measurable in body fluids and which may provide alternative or 
complementary tools to describe disease processes or to assess responses to 
pharmacological treatment. The focus of this thesis is inflammatory biomarkers, mediators, 
chemokines and cytokines that attract immune cells and that regulate the course of the 
inflammatory process at the site of inflammation. A major objective was to evaluate the 
behavior of these molecules in blood. 
In the first study we used two established animal models, the Freund´s Complete Adjuvant 
(FCA) model and the Carrageenan model, to induce experimental inflammation in rats and 
could demonstrate a significant decrease of prostaglandin E2 (PGE2) in synovial fluid 
following treatment with two COX-inhibitors, naproxen and rofecoxib, despite the drugs 
having limited efficacy on overall joint swelling. L(+)-lactate, the end product of glycolysis, 
reflects cell activity and was therefore hypothesized to be a suitable novel indicator of 
experimental inflammation. We found that L(+)-lactate levels were unaffected by COX-
inhibitors in this study, indicating that L(+)-lactate might be used as a biochemical biomarker 
for on-going inflammation in individuals being treated  with COX-inhibitors. In the next study 
we therefore assessed levels of L(+)-lactate, as well as chemokines and cytokines, in joint 
fluids from human osteoarthritis patients and in an additional animal model, the monoiodo 
acetate (MIA) model, which primarily induces cartilage degradation, osteophyte formation 
and mild synovitis. MIA induced distinct inflammatory biomarkers in a biphasic manner, but 
in considerably lower amounts than FCA, suggesting that the underlying pathology in these 
two models is significantly different. As expected, L(+)-lactate was readily detectable in 
synovial fluid in the MIA model and in humans, correlating with the levels of cytokines and 
chemokines, and thereby indicating the presence of inflammatory cells in the joint cavity. 
We also observed two common findings between the MIA model and in humans, namely 
the presence of IL-6 in joint and serum and the lack of IL-1β and TNF in the same matrices. 
Nevertheless, we found it difficult to identify a single systemic biochemical biomarker that 
specifically reflects an ongoing local inflammatory process in osteoarthritis, and nor was it 
possible to identify a specific translational biomarker between the animal models and OA 
individuals.  
In the third study, in rats subjected to spinal cord injury, the main findings were changes in 
inflammatory biomarkers in serum during the time of treatment with the drug imatinib, a 
tyrosine kinase inhibitor. Although serum levels of MCP-1 and MIP-3α were increased at day 
1 following injury or sham injury, levels remained similar or lower throughout the study up 
to 7 days whereas MCP-1 and MIP-3α were further increased at 7 days following injury in 
the imatinib group. It is plausible that our findings will translate to humans and that the SCI 
individual could be its own control. Nerve Growth Factor (NGF) is released following tissue 
injury and therefore the aim was to determine whether NGF is released into the synovial 
fluid in the FCA model. In the last study we reported the successful development of an assay 
for the measurement of rat NGF in synovial fluid in rats exposed to FCA. We conclude that 
the usage of biochemical biomarkers has wide application, and may be used as a 
complementary tool to other readouts for the analysis of inflammatory conditions. 
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1 INTRODUCTION 
 
1.1 General background on biomarkers 
 
The term biomarker and its application were first mentioned in the 1990s 
and have since been used extensively, especially in the pharmaceutical industry in 
connection with the development of drugs (Bowsher et al, 2012). There are several 
definitions of the term biomarker, but the most accepted description, given by the National 
Institutes of Health (NIH), is as follows "a characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes or 
pharmacological responses to a therapeutic intervention." (Biomarker Definitions Working 
Group, 2001). Biomarkers can be biochemical, biomechanical or bio-physiological. 
Biochemical biomarkers are components like small proteins, lipids etc that are 
experimentally induced or naturally occurring, which are measurable in mammalian body 
fluids and gives information about what is happening in the body. Soluble biochemical 
biomarkers are by classification divided in groups corresponding to diagnostic/disease 
markers, efficacy markers, prognostic markers or markers that reflect other interventions 
such as induced inflammation. Examples of biomechanical and bio-physiological biomarkers 
are electrocardiography (ECG), blood pressure, pulse and fever which are measured using 
equipment such as stethoscopes, watches, thermometers and non-invasive instruments for 
the evaluation of medical state.  
Soluble protein biomarkers are frequently used to diagnose diseases and assess positive or 
negative responses to medication, both in the clinic and during clinical trials. For example, 
testing for levels of the protein known as C-reactive protein (CRP) can help doctors to detect 
the degree of inflammation or infection. An increasing number of patients are affected by 
diseases caused by inflammation or do suffer from injuries where inflammation are a part of 
the dysfunctional outcome. Our focus is therefore to identify and validate reliable 
biochemical biomarkers that may provide as an alternative or complementary tool, which 
more reliably describe disease processes caused by inflammation, at an early stage.  
 
1.2 Biochemical biomarkers 
1.2.1 Biochemical biomarker development process 
The optimal soluble biochemical biomarker should be easy to obtain. Therefore biomarkers 
that can be detected in serum or plasma from blood, urine or saliva are superior to body 
fluids such as synovial fluid and cerebrospinal fluid, as the access to the latter is limited due 
to the invasive sampling techniques needed, and the unwillingness of the patients to donate 
those samples.  
On the other hand, there are challenges (due to low levels, lack of appropriate methods etc) 
when trying to identify soluble markers in peripheral blood that correlates with disease 
activity at the site of injury (eg. joints, spinal cord, brain,) because a proportional and 
sufficient diffusion of the marker from the affected site has to take place. Another challenge 
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is to identify efficacy markers representing the outcome of a specific drug, such as achieving 
the optimal time points for assessment. Furthermore, insights to which biomarkers that 
covary between animal models and human disease will facilitate translation of preclinical 
data to studies aimed at identifying targets for disease and symptom therapies. A biomarker 
for the efficacy of a drug, preferably present in blood, may further support stratification 
variables for analysis of outcome in translational studies, due to the knowledge that not all 
patients are responders to the given drug. 
The development of a biochemical marker is a process consisting of 5 overlapping steps (Fig. 
1) (Lee JW, 2009). The ultimate final product is a surrogate biomarker that shows so good 
correlations with the patient’s symptoms that it can replace clinical readouts as the primary 
efficacy endpoint in clinical phase 2 or 3 trials and that to be used in the healthcare 
regularly. 
 
 
Figure 1. Schematic schedule describing the biomarker development process.  
Modified from Lee, JW (2009). 
 
1.2.2 Exploratory method validation 
The most common methods and techniques used for the investigation and/or measurement 
of biochemical biomarkers are immunoassays, based on absorbance (conventional ELISA), 
electro chemiluminescence (MesoScale Discovery platform) or fluorescence. Other methods 
useful in the early biomarker discovery are the proximity ligation assay (PLA), 
electrophoresis (Western Blot), gene expression assays (quantitative real time PCR) and 
mass spectrometry (Shah et al, 2007). The focus in this thesis is biomarker discovery, and 
partially also demonstration of some markers. Both methods and inflammatory biomarkers 
will be presented and discussed from several aspects. 
 
Biomarker level variation 
Biomarkers may be expressed at different levels depending on the matrice that is used 
(DaSilva et al, 2014). It is important to  evaluate if it matters if serum or plasma are used for 
detection of the biochemical markers we explored in this study, especially if they are 
dependent on clotting factors.  
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Validation of immunoassays for biochemical biomarkers 
The critical parts for immuno assays are the capture and detection antibodies, they have to 
be of good quality, be specific for the target and do not cross-react with related proteins.  
Therefore fit-for–purpose method validations i.e. check for linearity, state the lower limit of 
quantification and define the minimum required dilution must be performed. Of importance 
is also stability tests of the marker of interest. Some proteins/cytokines/chemokines 
degrade fast and do not allow to be thawed several times. 
 
1.2.3 Interpretation of results  
In general two criteria are set by the manufacturers when presenting their immunoassay 
products. The use of the terms limit of detection (LOD), also called sensitivity, and low limit 
of quantification (LLOQ) needs to be explained. Sensitivity value refers to the lowest 
measurable value that is statistically not equal to zero (example from R&D systems, ELISAs) 
while the LLOQ is the lowest concentration at which the coefficient of variation (CV) of the 
calculated concentration is <20% (or <25) and the recovery of each analyte is within 80% to 
120 % of the known value (example from Mesoscale Discovery). The quantitative range of 
the assay starts at low limit of quantification and ends at the upper limit of quantification. 
Limit of detection should not be used in other cases than for a yes or no answer. 
Furthermore, when large series of samples are assayed, it is useful to have a batch of 
controls for the evaluation of inter-assay variability through the study. Pharmaceutical 
companies and their biomarker laboratories might have even more defined criteria due to 
own validation but those numbers above are set by most of the manufacturers. 
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1.3 Osteoarthritis  
Osteoarthritis (OA) is a common joint disease, approximately 25% of the population >45 
years are affected in Sweden (Englund et al, 2014). OA is characterized by a mild intra-
articular inflammation with limited synovitis, degeneration of articular cartilage, and 
changes in peri-articular and subchondral bone. OA was traditionally considered to be a 
“non-inflammatory” arthritis, as it lacks the pronounced systemic and intra-articular 
inflammatory response that is the key feature of rheumatoid arthritis. 
However, signs of inflammatory processes such as increased cell proliferation and synthesis 
of proteinases, growth factors, cytokines, and other inflammatory mediators by 
chondrocytes have been detected in early stages of the disease. 
Release of IL-1β, TNF and IL-17 have been detected in the OA joint and are thought to 
contribute to the pathogenesis of OA through several mechanisms, including down 
regulation of anabolic events and up regulation of-catabolic and inflammatory responses, 
effects that result in structural damage of the OA joint (Kapoor et al, 2011).  
The later stages of OA pathology are thought to be due to excessive wear and tear in the 
joints. The factors that drive the disease progression are still not completely understood, but 
e.g. mechanical influences such as load, aging of cartilage matrix, and genetic factors are 
important. Changes in other cells and tissues of the joint, including the synovium and 
subchondral bone, are also thought to contribute to pathogenesis (Goldring et al, 2007) 
(Goldring et al, 2011).  
 
Figure 1. Picture illustrating the proinflammatory cytokines and the cells involved in the pathophysiology of OA. 
Picture modified from Kapoor et al. Nat. Rev. Rheumatol. 7,33-42 (2011). Courtesy of Jie Su. 
 
Pain is the main reason why these patients seek health-care/medical attention. The disease 
is chronic by nature and there are no effective disease modifying therapies. Thus, the 
patients are left to use pharmacologic or alternative therapies to reduce the joint pain and 
when this is not effective, surgical interventions such as joint-replacement (Kapoor et al, 
2011) is performed.  
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Today the diagnosis of the disease relies on clinical and radiological features and nearly half 
of patients of osteoarthritis have no symptoms and vice versa. Thus biochemical biomarkers 
may provide an alternative or complementary tool that more reliably describe disease 
processes also at an early stage, and concur with the symptoms. Also, the identification of 
biomarkers that concur with development of OA-like pathology and symptoms in 
experimental models of OA would facilitate the search for new therapies for disease control 
and symptom relief. Such factors are searched for by taking e.g. a metabolomics approach 
(Zhai et al, 2012). Also, intriguing work focused on inflammatory biomarkers is ongoing, but 
more research is needed, especially when attempting to find soluble biomarkers in the 
periphery reflecting an on-going disease process in the joint.  
 
1.4 Spinal Cord injury (SCI) 
Spinal cord injury affects 12 000 individuals per year in the U.S. and 6 000 to 10 000 
individuals (in total) in Sweden have been diagnosed with SCI. There is no drug treatment 
in use that convincingly shown to has improve the functional recovery after SCI. 
(www.hjarnfonden.se/diagnoser/ryggmargsskada). Depending on at what level of the 
spinal cord the injury take place, different types of malfunctions will occur. Cervical lesions 
may result in tetraplegia while thoracic injuries may result in paraplegia. It is also common 
that SCI leads to apparent loss of sensation below the injury, and that tissues 
corresponding to “at-level” and “above-level” become hypersensitive. Another frequent 
and problem resulting from SCI is the inability to control or empty the bladder, as well as 
erectile dysfunction, because the nerves regulating these functions descend from the 
sacral part of the spinal cord. Spinal cord injury progresses in two stages, firstly a damage-
causing incidence, after that an extended period when additional loss of cells and nerve 
fibers will occur and inflammatory and scar forming processes will predominate. During 
the secondary event there is a possibility that pharmacological intervention may decrease 
the extent of permanent neurological impairment. 
Inflammatory cytokine responses after spinal cord injury have been investigated 
experimentally and clinically, and may constitute biomarkers for secondary events after 
spinal cord injury (Krishna et al, 2014, Steeves et al, 2012). Moreover, the drug imatinib has 
been shown to exert direct effects on the immune system, for example, altering the 
inflammatory cytokine/chemokine response in serum during treatment of chronic 
myelogenous leukemia (Adzemovic et al 2013, Hayashi et al, 2012, Pardanani et al, 2003, 
Seggewiss et al, 2005, Cools et al, 2003). 
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1.5 Animal models of disease 
1.5.1 OA-related joint inflammation and joint pain 
   
Different animal models are utilized in order to not only increase our understanding of the 
molecular events that occur in joint tissues at the onset and during the progression of OA, 
but also to delineate the mechanisms that drive OA-induced pain (Gregory et al, 2012, Orita 
et al, 2011). Examples of common rat models of joint inflammation and/or OA like 
pathology are: i) the carrageenan model ii) the Freund´s complete adjuvant (FCA) and iii) the 
monoiodo acetate (MIA) model. The carrageenan model is induced by an intra-articular 
injection of carrageenan to the joint, which induces an inflammation based on rapid 
infiltration of granulocytes to the site of injection. This model is relatively short lasting with 
sign of inflammation and pain lasting for 24-48 hours. The FCA model is established by with 
an emulsion including adjuvant and a mycobacterial protein, injected intra-articularly. This 
model causes both joint inflammation and cartilage degradation is more long-lasting (1-3 
weeks) compared to the carrageenan model. The MIA model is induced by intra-articular 
injection of monoiodo acetate, which generates a low-grade long-lasting (weeks) 
inflammation and cartilage loss (Orita et al, 2011, Guingamp et al, 1997). Subchondral bone 
is also affected. However, no consensus exists regarding if any of these models are relevant 
for human OA. Hence, while the different animal models provide information on joint 
biology and OA pathology, differences between the models also makes comparisons 
between studies difficult and the translation of animal results to human OA challenging. 
 
1.5.2 SCI 
The most common method to subject rats to spinal contusion injury is by using a dedicated 
instrument called Impactor. (Abrams et al, 2012, Gruner J.A, 1992, Kjell et al, 2013) 
The dorsal surface of the spinal cord is exposed by laminectomy of the spinal column (at T9 
and the caudal half of T10) and by dropping a 10 g weight from a specified height onto the 
spinal cord e.g. 12.5 or 25 mm to induce a mild or moderate contusion injury, 
respectively. Mild injury typically results in all animals being able to support their own 
weight with the hind limbs, which allows sensory testing and automated locomotor 
assessment. 
A moderate injury results in none to a few animals able to weight support and does not 
allow the above behavior tests. Furthermore, in contrast to a mild injury, a moderate injury 
typically results in less variability for the assessed parameters of locomotor recovery and a 
more robust cytokine response originating from the injured spinal cord. Depending on the 
readouts the most appropriate model has to be chosen. 
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1.6 Inflammation 
1.6.1 The inflammatory process 
Inflammation is the innate immune system response to an infection caused by a pathogen, 
tissue injury caused by e.g. blunt force, tissue penetration or damaging heat or cold, or 
exposure to irritants or toxins, which involves the local vascular system, recruitment of 
leukocytes to the initiating site and release of molecular mediators. The inflammatory 
process is critical as it protects the body by isolating the damaged area, cause release of 
mediators such as chemokines and cytokines that attract immune cells and regulate the 
course of the inflammatory process at site and, in later stages, promote the healing of 
affected tissues. 
 
Acute inflammation  
Acute inflammation can occur within minutes of the injury, but it can also take several hours 
before the inflammatory response has fully developed. An acute inflammation starts by the 
movement of plasma proteins and leukocytes cells from the bloodstream into the injured 
tissues. Release of prostaglandins (PG), histamin and other mediators from local resident 
inflammatory cells (e.g. macrophages and mast cells) cause blood vessel dilatation, resulting 
in a local reduction in blood pressure and allows the circulating leukocytes to get in contact 
with the endothelial cells. 
The recruitment of leukocytes to the site of inflammation is a multistep process involving i) 
attachment of circulating leukocytes to endothelial cells ii) migration through the 
endothelium iii) penetration into the tissue and iiii) cellular activation and response to the 
injury or infection. In most forms of acute inflammation, neutrophils, which respond rapidly 
to chemokines, predominate in the inflammatory infiltrate during the first 6 to 24 hours, 
after that they are replaced by monocytes/macrophages in 24 to 48 hours. Local release of 
cytokines, including chemotactic factors, induce a number of responses in leukocytes such 
as further production of arachidonic acid metabolites e.g. PGE2, degranulation and secretion 
of lysosomal enzymes, modulation of leukocyte adhesion molecules and secretion of 
cytokines.  
This process causes the symptoms that are typically associated with inflammation, including 
redness, swelling and pain, and in some cases increased body temperature and loss of 
function in the immediate area. When the injury starts to heal or the source of infection has 
been neutralized, the symptoms of inflammation also resolve. However, if the inflammatory 
trigger remains active or repeatedly reoccur, the inflammation may develop into a more 
chronic state (Wold et al, 2007)  
Chronic inflammation 
Many of the features of acute inflammation continue also in state of chronic inflammation, 
for example, the blood flow and the capillary permeability are still increased and the 
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recruitment and accumulation of white blood cells continues. Chronic inflammations is 
primarily mediated by monocytes and long-lived macrophages and at later stages, other 
cells, including lymphocytes are recruited to the site of inflammation. Macrophages 
phagocytize pathogens/irritants at the site of the inflammation and they are important 
secretory cells releasing inflammatory factors. Thus activated macrophages are the main 
source of the cytokines that are involved in inflammation, but other leukocytes and mast 
cells also contribute. Lymphocytes entering the inflamed tissue can serve several roles. For 
example T-cells activate macrophages in a pathogen/antigen-dependent manner and T-cells 
can directly kill virus-infected cells. B-cells produce antibodies that specifically target 
invading microorganisms or tissues for destruction. Repair of the damaged tissue is 
important for return to homeostasis, and for this the damaged cells are replaced with cells 
of the same type or with fibrous connective tissue. Chronic inflammation is involved in a 
number of disease states when the body is unable to repair tissue damage.  
(http://course.washington.edu./conj/inflammation/chronicinflam.htm) 
 
The immune cells are dependent on glucose as an energy source to perform the described 
effector functions, and cortisol increases the glucose levels in blood during inflammation. 
Increased glycolysis is well-known pathway by which macrophages regenerate their energy 
stores during phagocytosis and it is also established that aerobic glycolysis contributes to 
lactate (a pyruvate metabolite) accumulation in the presence of oxygen, especially under 
inflammatory conditions (Maciver et al, 2008). The level of glucose metabolism can be 
monitored using non-invasive FDG-PET imaging as a biomarker of the intensity of cellular 
activity at the sites of inflammation. The level of lactate may be a soluble biochemical 
biomarker depicting the degree of inflammation, as described in paper I. 
 
1.6.2 Inflammatory mediators 
As mentioned above, while an injury, disease or pathogen invasion typically starts the 
inflammatory process, there are a variety of chemical factors, which affect, stimulate, and 
control the inflammatory process. The pattern of soluble cytokines and other cell markers 
expressed will reflect whether a pro-inflammatory or anti-inflammatory reaction is ongoing 
at the inflammation site. Typical pro-inflammatory markers include, IL-1, IL-6, TNF-α, IL-12, 
IL-17, IFN-γ, MCP-1, MIP-3α, sICAM-1. Typical anti-inflammatory markers are, but are not 
limited to, IL-4, IL-10, IL-5 and TGFβ. Some of the factors with more prominent roles are 
described below. 
 
Prostaglandin E2  (PGE2) 
 
Prostaglandins are small-molecule lipid mediators that are derivatives of arachidonic acid. 
They are produced by two cyclooxygenases (COX), the constitutively active cyclooxygenase 
COX-1 and the inducible COX-2, followed by the action of different prostaglandin synthases. 
At the site of inflammation PGE2 contributes to local increases in blood flow and therefore 
starting edema formation by agents such as bradykinin and histamine. Furthermore, PGE2 
also promotes inflammatory pain by sensitizing afferent nerve endings.   
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Agents such as non-steroid anti-inflammatory drugs (NSAIDs) and glucocorticoid steroids 
represent some of the most common and effective pharmaceutical agents to inhibit or block 
prostaglandin production. (Giuoli et al 2002, Kalinski et al, 2012).  
Nerve growth factor (NGF) 
Several studies have shown that under the inflammatory process, there is a local increase 
of NGF at the site of inflammation (Prencipe et al, 2014). NGF belongs to a family of 
neurotrophins, a group of proteins that have similar structures and functions. Immune 
cells express the NGF receptors, tyrosine kinase A (TrkA) and neurotrophin p75 (p75-NTR). 
TrkA is specific for NGF whereas p75-NTR binds all neurotrophins with equal affinity. 
Activation of TrkA receptor leads to production and release of pain inducing 
neuropeptides such as substance P (SP) and calcitonin-gene related peptide (CRRP). NGF 
also directly sensitizes sensory nerve cells via as pain fibers express TrkA receptor and 
activates signal transduction. These activated pathways phosphorylate transient receptor 
potential (TRP) channels, which in turn increases excitability of pain neurons (MacMahon 
S, 1995, Bracci-Laudiero L, 2010). Of note, increased NGF concentrations have been 
observed in the synovial fluid of patients with rheumatoid arthritis and in serum of 
systemic lupus erythematosus (SLE), closely following the progress of the disease (Bracci-
Laudiero L, 2010) Further, NGF mRNA expression and protein levels are increased in 
synovial fluid in animal models of inflammation such as carrageenan-induced or Freund's 
complete induced adjuvant arthritis. 
Cytokines/Chemokines 
 
Interleukins and chemokines such as IL-6, IL-8, IL-1β, TNF, MCP-1 (CCL-2), MIP-3α and the 
prostaglandin PGE2 might represent biochemical biomarkers of inflammation and/or pain in 
OA. As metabolic cell-activity may covary with the inflammatory process in the joint the 
utility of measuring the pyruvate metabolite L(+)-lactate will add further information about 
the state of the inflammation.  
 
1.6.3 Why these biochemical biomarkers? 
Among the proinflammatory cytokines involved in osteoarhtritis, IL-1β and TNF are 
considered the major players (Miller et al, 2014, Kapoor et al, 2011, see fig 1, Ru Liu-Bryan et 
al, 2013) and these are the two most extensively studied. These are produced by 
chondrocytes, mononuclear cells, osteoblasts and synovial tissues. Furthermore, both IL-1β 
and TNF are thought to diffuse into synovial fluid and act on chondrocytes to suppress 
matrix synthesis. They also induce expression of other cytokines such as IL-6 and IL-8, and 
promote cartilage catabolism by producing matrix-degrading enzymes in both chondrocytes 
and synoviocytes. 
 
IL-6 is a pluripotent cytokine thought to be a key player in systemic inflammation and 
arthritis, and on-going discussions and studies explore whereas it is a pain trigger or not. 
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Previous studies demonstrate that synovial fluid IL-6 levels could help to classify OA patients 
and may point to a subgroup with a particular impact from their immune system (Svensson 
CI, 2010, Doss et al, 2007). 
 
MCP-1 (CCL2) is member of the C-C class of the beta chemokine family and mainly involved 
in the initiation of inflammation, e.g. it is a potent chemoattractant for monocytes and 
macrophages to the area of inflammation (Deshmane et al, 2009).  
 
MIP-3α, a CC (cysteine cysteine motif) chemokine ligand, CCL20, is chemotactic, not only for 
dendritic cells but also for (memory) T-cells and studies indicate that MIP-3α and its 
receptor CCR6 may function to recruit monocytes and memory lymphocytes from the RA 
peripheral blood into the RA joint (Chabaud et al 2001, Ruth et al, 2003). Recently, it has 
been confirmed that increased levels of CCL20 are expressed in subchondral bone tissue of 
rheumatoid arthritis patients (Lisignoli et al, 2007). The same author suggested a differential 
role of this chemokine in OA and RA regarding proliferative response in osteoblasts 
(Lisignioli, 2009). 
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2 AIMS OF STUDIES 
 
 
 Investigate if L(+)-lactate can be used as a covariat marker for inflammation and/or 
pain-like behavior in animal models of joint pain.  
 
 Examine if cytokines and chemokines are present in the synovial fluid and blood in 
animal models of joint pain and investigate the potential of these factors as 
biochemical biomarkers of inflammation and/or pain-like behavior. 
  
 Examine if L(+)-lactate, cytokines and chemokines as potential biomarkers of 
pain/inflammation in patients with osteoarthritis. 
 
 Examine if there is a candidate/possible biochemical biomarker of inflammation in 
spinal cord injury in rats, after and before specific treatment with imatinib. 
 
 Examine if rat Nerve Growth Factor (NGF) is present in the synovial fluid in animal 
models of joint pain and investigate the potential of these factors as biochemical 
biomarkers of inflammation and/or pain-like behavior.  
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3 STUDY DESIGN 
 
 
Table I.  Study design. 
 
 
Phase Intervention/model Paper I Paper II Paper III Paper IV Paper V 
 Rat Synovial fluid Synovial fluid/Serum Serum  Synovial 
fluid 
D
is
co
ve
ry
 
Carrageenan (Cg) L(+)-lactate, PGE2 
w/wo NSAIDs 
    
Freund´s Complete 
Adjuvant (FCA) 
L(+)-lactate, PGE2 
w/wo NSAIDs 
L(+)-lactate (in SF) 
IL-1β, TNF 
MIP-3α 
IL-6 
KC/GRO 
MCP-1 (CCL-2)  
  NGF 
Monoiodo-acetate 
(MIA) 
 L(+)-lactate (in SF)  
IL-1β, TNF 
MIP-3α 
IL-6 
KC/GRO 
MCP-1 (CCL-2)  
   
Spinal Cord Injury (SCI) 
(Uninjured, sham- injured 
and injured) 
  MIP-3α  
KC-GRO 
IL-6 
w/wo 
Imatinib 
  
 Human  Synovial fluid/Serum  #  
D
em
o
n
st
ra
ti
o
n
 Osteoarthritis (OA) 
(with individual 
treatment) 
 
Healthy age matched 
individuals (only serum) 
 L(+)-lactate ( in SF)  
IL-1β, TNF 
MIP-3α 
IL-6 
IL-8 
MCP-1 (CCL-2)  
   
 
 
 
Treatment for the OA individuals was either celecoxib or prednisolone. The biomarkers, Interleukins 
(IL-s), macrophage inflammatory protein 3α (MIP-3α), monocyte chemoattractant protein 1 (MCP-1), 
tumor necrosis factor (TNF) and L(+)-lactate were assessed either by immune assay or by a 
colorimetric method. The NSAIDs used were naproxen or rofecoxib, w/wo (= with or without). 
KC/GRO in rats represents IL-8 in humans. A multiplex (10-plex) was used for the measurements of 
cytokines and chemokines including INF-γ, IL-1β, TNF, IL-6, IL-2, IL-4, IL-5, IL-10 and IL-13 and KC/GRO 
(Paper III)  
 # In Paper IV, no formal biomarker discovery was performed, only methodological aspects. 
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4 MATERIALS AND METHODS 
4.1 ETHICS STATEMENT 
All animal experiments were carried out in accordance with protocols approved by the 
Stockholm Ethics Committee for Animal Experiments (Stockholms Norra och Södra 
Djurförsöksetiska Nämnder, Sweden) with approval numbers S80/04, S120/06, S111/07, 
S13/09 S87/11, N623/12, (paper I, II and V), N479/11 and N100/13 (paper III).     
All human samples (paper II) were collected with written informed consent under the 
required IRB/ethics approval (Tissue Solutions Ltd.). The research was approved by the 
regional Swedish ethical board, ethical permit number 2011/743-31/1, paper II, and for 
paper IV permit number M75-09. 
 
4.2 ANIMAL MODELS 
The animals were housed in transparent Macrolon® cages (3–6 rats per cage) with wooden 
shavings or thick sawdust as bedding, with free access to food (R70, Lactamin AB, Vadstena, 
Sweden) and tap water. The lighting was controlled with a dark/light cycle 12:12h (or ± 0.5 h 
for dusk and dawn). The temperature was set to 20 °C and the animals were acclimatized for 
at least 7 days before onset of the experiments. For the spinal cord injury rats the 
temperature in the animal room was kept at 24–26°C.  
 
Carrageenan-induced monoarthritis: (Paper I) Adult Sprague-Dawley male rats (B&K 
Universal, Sollentuna, Sweden), 230 ± 15 g body weight) were anesthetized by 5% isoflurane 
in air and 50 µL of -Cg (7.5 mg/mL in saline; Sigma, Sweden) were  injected into the left 
tibio-tarsal ankle joint from the dorsal side. Naïve (non-injected) rats were used as controls. 
 
FCA-induced monoarthritis: (Paper I, II and V) Male Sprague-Dawley rats (B&K Universal, 
Sollentuna, Sweden, 215 ± 245 g body weight or Harlan Laboratories B.V., Horst, The 
Netherlands, 225-250 g), were anesthetized by 5% isoflurane in air, and FCA (Sigma; 1 
mg/mL; 50 µL) was injected intra-articularly into the left ankle joint and synovial fluid was 
collected at specific time points up to 14 days post injection. . As control groups naïve rats 
were used (paper I) or rats that received intra-articular injection of 50 µL saline followed by 
collection of synovial fluid at 5 hrs (Paper II). Additional 40 Sprague-Dawley male rats 
(Charles River, Sulzfeld, Germany) were used in a separate study for biochemical analysis of 
NGF content in synovial fluid. These rats were induced with FCA monoarthritis or injected 
with saline and synovial fluid was collected 1, 2, 5 and 10 days post FCA injection and 1 and 
10 days following saline injection. 
 
MIA-induced monoarthritis: (Paper II) Lewis male rats (Harlan Laboratories B.V., Horst, The 
Netherlands, body weight 210-250 g, n=8/group) were anesthetized by 5% isoflurane in air 
and MIA (Sigma; 2 mg in 25 µL saline) was injected intra-articularly into the left knee joint 1, 
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2, 4, 7, 10, 17, 21, 28 and 35 days prior to termination.  At day 1, MIA groups were matched 
with control groups that were injected with 25 µL saline intra-articularly. 
 
Spinal cord injured animals: (Paper III) Sprague–Dawley female rats (Scanbur, Germany, 
body weight 200-275 g) were used.  Spinal cord injury was performed by a specific 
instrument (NYU Impactor, Keck Center for Neuroscience) as previously described In brief, 
rats received analgesics before the surgery and under anesthesia (isoflurane) the dorsal 
surface of the spinal cord was exposed by laminectomy (sham injury), and by dropping a 10 
g weight from a height (12.5 or 25 mm) onto the spinal cord the contusion injury was 
induced.  
 
4.2.1 Drugs and drug administration 
 
In Paper I the pharmacological effect of orally administered drugs were evaluated. 
Naproxen (naproxen sodium salt in tap water; Sigma, Sweden) 7.5 or 30 µmol/kg, or 
rofecoxib (Vioxx, Merck Sharp & Dohme, Sweden), 30 µmol/kg, was administered orally, 2 
and 48 hrs post injection of carrageenan and Freund´s Complete Adjuvant, respectively. In 
paper III Imatinib tablets were grinder into powder and suspended in 0.1 M PBS, brought to 
37 °C for 5 min and then centrifuged at 13000 RCF for 2 min. The supernatant was 
transferred to a new tube and stored at room temperature (max 2 hrs) until administration. 
Imatinib treatment was given by gavage (250 mg/kg) either 4, 8, or 24 hours after contusion 
injury and continued daily for 14 days. One third of the daily dose was administered in the 
morning the remaining dose in the afternoon.  
 
4.2.2 Sample collection 
 
Collection of blood and synovial fluid (FCA and MIA animals) 
  
The rats were anesthetized with isoflurane at different time points after induction of FCA or 
MIA monoarthritis and blood collected by cardiac puncture was divided into eppendorf 
tubes, for preparation of serum, or into tubes containing EDTA. The serum samples were left 
in room temperature approximately 30 min followed by centrifugation at 4°C (4800 x g, 10 
min) and EDTA samples were kept on ice prior to centrifugation at 4°C (4800 x g, 10 min). 
The supernatants were transferred to eppendorf tubes and stored at -80oC until analysis. 
For the collection of synovial fluid the animals were sacrificed by intra-cardiac injection of 1-
2 mL pentobarbitural. The skin above the ankle or the  knee joint was cut transversally and 
the ligament above the joint was punctuated with a scalpel, and the synovial fluid collected 
by lavage with 25 μL 0.05M EDTA (Sigma, pH 7.5). The lavage was repeated 4 times. The 
fluid was kept on ice until centrifugation (maximum 1 hour) at 4°C, (3800 x g, 10 min) and 
the supernatants stored at –80oC until biomarker analysis. 
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Collection of blood (SCI animals) 
  
Blood from the SCI animals was collected at days 1, 3 and 7 post injury. Rats were put in a 
cage heated by a heating pad for 15 min prior to blood sampling.  Thereafter the animal was 
moved into a plastic constrainer and 250 µL of blood was collected from the tail vein. The 
blood was kept at room temperature for 20-30 min prior to centrifugation at 4°C (4800 rpm 
for 10 min). The supernatant was collected and transferred to – 80 °C prior to analyze. 
 
4.3 Assays 
4.3.1 Colorimetric assay 
 
L(+)-Lactate levels were measured  by a colorimetric assay (#K607, BioVision, CA, USA). The 
method described by the manufacturer was slightly modified by converting the 
concentrations to mmol/L and extending the standard curve. In brief, samples were diluted 
up to 1:32 with the provided kit buffer and transferred to a 96-well microplate and mixed 
with an equal volume of the provided reaction mix (lactate oxidase and lactate probe). After 
30 min of incubation at room temperature, the microplate was read at 570 nm on a 
Spectramax 340 (Molecular Devices, Sunnyvale, CA, USA). Lower limit of quantification for 
L(+)-lactate was 0.02 mmol/L.  
 
4.3.2 Immunoassay 
Prostaglandin E2 (PGE2) 
  
PGE2 levels in the synovial fluid samples were analyzed using a PGE2 radioimmunoassay KIT 
(RPA 530, GE Healthcare, Uppsala, Sweden). The assay was performed according to the 
manufacturer’s instructions, with the exception that the volume of the oximation reagent 
was adapted to the viscosity of the samples.  
 
Cytokines and Chemokines 
 
All assays were performed using the electro chemiluminiscence (ECL) technique. 96-well 
plates, pre-coated with antibodies towards the analytes of interest, were blocked with the 
provided diluent for 30 min, thereafter plasma/serum or synovial fluid samples, diluted 1:2 
or 1:4 respectively in assay diluents, were added to the wells and the plates were incubated 
for 2 h. Following washing of the plates, MSD Sulfo TAG secondary antibody mixtures were 
added and the plates were incubated for an additional 1.5 hrs. All incubations were 
performed at room-temperature. After a final washing step, read buffer (2X) was added and 
the plates analyzed on a SECTOR Imager (SI6000, MesoScale Discovery). 
 
In house developed immunoassay for rat NGF 
 
An immunoassay for analysis of rat NGF was developed using electro chemiluminescence 
(ECL) technique. Plates were coated with Rat beta-NGF antibody (Cat No AF-556-NA), 
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blocked with 3% BSA for 30 minutes and subsequently washed. Recombinant Rat beta-NGF 
(Cat No 556-NG-100/CF) was used as a calibrator. Synovial fluid samples, diluted 1:4 in assay 
diluents, were added to the wells and the plates were incubated for 2 h. Following washing 
of the plates, Rat beta-NGF biotinylated antibody (Cat No BAF556), added with MSD Sulfo 
TAG, was dispensed to all wells and the plates above. Lower limit of quantification was 9.77 
pg/mL. 
 
4.4 Statistics 
To compare the treatment groups in Paper I, statistical evaluation of PGE2 and lactate levels 
was performed by using an unpaired t-test, Graph Pad Prism 4 software (GraphPad 
Software, La Jolla, CA, USA). The effect of the anti-inflammatory drugs on the degree of 
inflammation was evaluated by using Kruskal–Wallis one way analysis of variance (ANOVA) 
on ranks (non-parametric data) followed by Dunnett’s test to compare the vehicle-treated 
group to the treated groups. Statistical significance was set at p<0.05. Results are presented 
as mean ± SEM (Paper I).  
Time course of inflammatory biomarkers from the animal studies (FCA and/or MIA injected 
rats) were presented as mean level together with 95% confidence interval for each time 
point (Paper II and V). No formal hypotheses were tested in the FCA evaluations in Paper II. 
All statistical analyses in Paper II were performed using either GraphPad Prism version 6.00 
or SAS/STAT version 9.3 of the SAS System for Windows (SAS Institute, Cary, NC, USA). In the 
MIA study, the response variables were evaluated in a regression model using study group 
(time point) as the exploratory variable. Before the model fit, a root transformation was 
applied to the response variables. The assumption of approximately normally distributed 
residuals in the statistical modelling process was thereby better fulfilled and the variance 
stabilized. In the humans, correlation between the two blood matrices as well as between 
the blood and SF were tested by calculating Pearson’s correlation coefficient together with 
the corresponding P-value. The difference between the two blood matrixes groups were 
compared in an ordinary t-test. Both the correlations and t-tests were based on log-
transformed data. The Mann-Whitney U-test was utilized to compare patients and controls 
with respect to cytokine levels.  
In Paper III Friedman test with Dunn’s multiple comparison test was used to analyze 
cytokine measurements for individual groups over time. Kruskal-Wallis test with Dunn’s 
multiple comparison tests was used to analyze cytokine measurements for three groups at 
one time-point. Linear regression analysis was used to determine correlations between 
axonal rescue and cytokine measurements, as well as between autofluorescence 
measurements of cord and spleen to MIP-3α measurements after Imatinib treatment.  
In Paper IV differences in IL-6 between freeze/thaw cycles were analyzed using the Mann–
Whitney U test. All values were reported as mean ± SEM. Reported p values are 2-sided. In 
this paper authors performed the analyses using SPSS Statistics version 20.0 (IBM Inc.) or 
Prism version 6.0 (GraphPad Software Inc.) 
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5 RESULTS 
 
 
Rats subjected to either Carrageenan (Cg) or Freund`s Complete Adjuvant (FCA) developed a 
time-dependent inflammation at the site of injection, the ipsilateral ankle joint, whereas no 
inflammation was observed at the contralateral joint. Joint swelling was measured by visual 
scoring (Paper I) or by using a three-button digital caliper (Papers II and V) to confirm 
inflammation.  
In Paper I, an intra-articular injection of either Cg or FCA caused an increase of prostaglandin 
E2 (PGE2) and L(+)-lactate in synovial fluid from the inflamed joint. Both markers showed a 
similar time course pattern, with a peak at 8 hrs in the carrageenan model. This observation 
is in contrast to the FCA model of inflammation where L(+)-lactate levels increased more 
rapidly (max at 24 hrs) as compared to PGE2 (max at 48-72 hrs). Both treatments, naproxen 
or rofecoxib, significantly decreased PGE2 levels but did not affect L(+)-lactate concentration 
in synovial fluid (Table II a). 
  
In Paper II levels of monocyte chemoattractant protein 1 (MCP-1), macrophage 
inflammatory protein 3α (MIP-3α), KC/GRO (IL-8 in humans), IL-1β, IL-6 and TNF were 
analyzed in synovial fluid, serum and EDTA plasma from two animal model Freund´s 
Complete Adjuvant (FCA) and monoiodoacetate (MIA), and from human subjects with 
osteoarthritis (OA). The aim was to identify soluble biomarkers of ongoing inflammation in 
the joint from a translational viewpoint.   
Levels of L(+)-lactate were measured in all joint fluids. In line with the findings of Paper I, we 
could confirm the same pattern and levels of L(+)-lactate in the FCA model and here the 
levels correlated with MIP-3α levels, with a peak at 24 hrs. Levels of L(+)-lactate differed in  
magnitude as well as in  temporal pattern between the two animal models, the MIA model 
expressed a biphasic pattern and levels were still increased at 35 days post-injection. Five 
individuals in the OA group had slightly to moderately higher L(+)-lactate levels in synovial 
fluid and one had extremely high levels compared to the lowest level of L(+)-lactate in this 
group. No normal/non-inflamed human synovial fluid was available (Table II b). 
Elevated levels of chemokines/cytokines were observed in the synovial fluid of 
monoarthritic animals as compared to control groups, although with considerably lower 
magnitude in the MIA groups, which also demonstrated a biphasic pattern. Levels of 
KC/GRO and MIP-3α in serum from the FCA model and IL-6 in the MIA model followed a 
similar pattern to that observed in synovial fluid. In serum samples from OA individuals, only 
MIP-3α correlated significantly with levels in synovial fluid (Table II b).  
 
In Paper III we aimed to determine if there were changes in inflammatory biomarkers in 
serum during the time of treatment that could be used as a biomarker to indicate an effect 
of a drug treatment. Imatinib was given four hrs following a moderately induced spinal cord 
injury (SCI) and then twice daily for seven days. For controls, we used rats that underwent 
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SCI without drug, as well as sham-injured and uninjured (naïve) animals with or without 
drug. Both MCP-1 and MIP-3α in serum were elevated at day 1 for all the surgery groups 
(injured and sham-injured) as compared to basal levels (uninjured). KC/GRO showed a 
different pattern at day 1, with a significant increase in the sham-injured group as compared 
to injured and uninjured groups, but with a decline to basal levels at day 7 post-sham injury. 
However, both MCP-1 and MIP-3α were further increased at 7 days following injury in the 
imatinib group in comparison with the other groups, in which levels remained similar or 
lower throughout the study (Table II c), Furthermore, each individual animal in the 
treatment group showed a significant increase of the three biomarkers MCP-1, MIP-3α and 
KC/GRO in serum as compared to their starting value at day 1 following injury, indicating 
that an individual can be its own control.  
 
Nerve Growth Factor (NGF) is released following tissue injury. In Paper V, one of the aims 
was to assess the presence of NGF in synovial fluid from rats exposed to FCA. A method for 
the measurements of rat NGF was successfully developed based on electro 
chemiluminescence technology.  The level of NGF in synovial fluid from rats injected with 
FCA was significantly increased, reaching a maximum at days one and two and thereafter 
declining but was still significantly increased at days 5 and 10 as compared to saline injected 
animals (Table II d).  
 
Methodological aspects 
 
All assays used in this thesis are based on electro chemiluminescence (ECL) technology with 
the exception the assay for L(+)-lactate which is a colorimetric assay. Given the very low 
levels of analytes, some of the biomarker results in Papers I, II, III and V are close to the low 
limit of quantification (LOQ), meaning that levels below LOQ cannot be accurately 
determined, but are evaluated as similar to LOQ, or close to, LOQ. All assays underwent a 
normal validation before measurement of the study samples. Interestingly, in paper II, MCP-
1 and KC/GRO (IL-8 in humans) showed different ranges and dynamics in serum and plasma 
in both the FCA model and in humans, with considerable lower levels in plasma. This 
observation has implications for the practical application of these assays in broader 
contexts. 
In Paper IV, we refer to low limit of detection (LOD), meaning that, as above, some values 
are estimated to be low or close to LOD. Due to limitations in sample volumes and frequent 
sample handling, it is of importance to check if the analyte of interest (IL-6 in cerebrospinal 
fluid) still shows reliable results at that low level due to sample age and freeze/thaw cycling. 
Therefore a stability test was performed to assess the effects of repeated thawing/freezing 
cycles of IL-6. No significant difference in IL-6 concentrations was observed between CSF 
samples, taken from -70◦ C, that was thawed once or after two thawing/freezing cycles. This 
suggests that the assay is indeed measuring IL-6 levels close to LOD. 
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5.1 TABLE II. Summary of results. 
 
a) 
 
 
Paper I 
Drug admin. 
post induction 
(hrs) 
Synovial fluid 
collected post drug 
admin. (hrs) 
 
PGE2 
 
L(+)-lactate 
Cg     
Cg + Naproxen 2 3    
  ***  
 
Cg + Rofecoxib 2 3    
  ***  
 
     
FCA   
  
FCA + Naproxen 48 3    
  ***  
 
FCA + Rofecoxib 48 3    
  ***  
 
 
   = increased levels compared to its own control group. ***P<0.001.  
Cg = Carrageenan, FCA = Freund´s Complete Adjuvant 
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b) 
 
Paper II Synovial fluid 
 Time 
points 
IL-6 KC/GRO 
IL-8  
MCP-1 MIP-3α IL-1β TNF L(+)-
Lactate 
FCA  5-48 hrs 
        
MIA 24-48 
hrs, and 
day 21, 
28 
a a a a _ _ a 
OA 
individuals 
 c c  
c _
d _d b 
  Correlation synovial fluid /serum  
 
 
 
 
 
   N/A 
FCA  no yes no yes no no 
MIA  yes no no no no no 
OA 
individuals 
 
no no no yes no no 
  Differences in serum levels 
OA/healthy 
individuals 
 
*yes no no no no no 
  Different distribution of serum and EDTA plasma 
FCA   no yes yes no no no 
OA   no yes yes no no no 
 
    = increased levels compared to its own control group (FCA and MIA),   --  = levels below or close to 
limit of quantification,   a = moderately increased levels compared to FCA, b = increased slight to 
extremely, c = one individual with extreme levels, d = all at the same level with one exception. *P<0.05 
N/A = not applicable 
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c) 
       
Paper III Serum levels compared to  baseline levels 
 MCP-1 MIP-3α KC/GRO 
time points (days) 
1 3 7 1 3 7 1 3 7 
Uninjured baseline 
Uninjured 
+ 
Imatinib 
(4 h) 
   
      
   
     
   
     
Sham 
injured 
***
 
    _     *
 
**
 
    _       _ ***
 
     _  
 
Spinal 
cord 
injury 
  
**
 
   
    _ 
  
**
 
   
    _ 
  
    _ 
     
     _ 
 
     _ 
 
     _ 
 
      _ 
Spinal 
cord 
injury + 
Imatinib 
(4 h) 
 
    _  
 
      _ 
  
 
*** e 
 
 
    _ 
 
 
 
 
*** e
 
 
     _  
 
     _ 
 
** e
 
 
  = increased levels compared to baseline levels in uninjured rats.  
   -  = no significant differences between groups of animals per time point. *P<0.05,   **P<0.01, ***P<0.001.        
  
e   = significantly increased compared to the injured group (spinal cord injury) that did not receive   
imatinib as well as to the sham group.  
   A multiplex (10-plex) was used for the measurements of cytokines and chemokines and no significant 
differences was found for INF-γ, IL-1β, TNF, IL-6, IL-2, IL-4, IL-5, IL-10 and  IL-13, although IL-6 differs 
slightly between the surgery models. Serum levels of MCP-1, MIP-3α, and KC/GRO were also affected by 
imatinib alone and induced a similar temporal pattern of increase as in injured imatinib treated animals, 
although the levels were not as high as in imatinib treated animals with spinal cord injury.  
 
d) 
 
Paper V NGF in synovial fluid 
 timepoints (days) 
1 2 5 10 
Saline baseline N/A N/A baseline 
FCA  *  *  *  
*
 
  = increased levels compared to baseline levels at day 1 and 10. *P<0.05.  N/A = not applicable. 
No significant difference between baseline levels at day 1 and 10 in the saline injected groups. 
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6 DISCUSSION 
 
 
The present study has focused on biochemical biomarkers, with an emphasis on 
inflammatory markers at the site of inflammation and in peripheral blood. In experimental 
trials of inflammation, biomarkers should reflect ongoing inflammation, the progression of 
inflammation and, depending on the designed purpose, should also reflect response to 
pharmaceutical treatment. Furthermore, knowledge as to which biomarkers covary 
between animal models and human disease will enable translation of preclinical data, and in 
the most optimal case, identify targets for disease and symptom therapies. The work 
presented in this study has addressed the optimisation of all these aspects. 
 
The development of a biochemical biomarker is a process consisting conceptually of five 
phases (Lee et al, 2009).The development of biomarkers is performed mostly in the initial 
discovery phase but also during the demonstration phase in the case of novel biomarkers. 
The discovery phase includes not only the measurement of an exploratory biomarker in 
animal studies or cell studies, but also the use of an appropriate assay. Since the majority of 
biochemical biomarkers are proteins, measured in biological matrices such as blood, 
synovial fluid or cerebrospinal fluid, immunoassays are the most commonly used method 
for quantification of the analytes. Most assays are commercially available, as RUO kits (for 
research use only, discovery-grade) (Bowsher et al, 2012, Lee et al, 2009). While these kits 
may have limitations in some cases, there are also advantages e.g, the kits are ready to use, 
simple to use and also cheaper in comparison with an in-house developed assay. Even with 
RUO kits, it is still necessary to perform a proper validation, before use of the intended 
application, to ensure that it measures the right biomarker in the right matrices at a correct 
level. 
 
Different animal models are used to induce pathology in rodents that resembles human 
joint disease. Common rat models of joint inflammation are the carrageenan model, the 
Freund´s complete adjuvant (FCA) model and the monoiodo acetate (MIA) model. The 
monoarthritis is induced by an intra-articular injection of the agent to the joint but the 
degree of the developed inflammation may differ within the group due to technical issues or 
to individual variability. In the acute phase of inflammation neutrophils infiltrate the 
synovial membrane and articular cavity. These inflammatory cells are dependent on glucose 
as an energy source and glycolysis contributes to lactate (the end product of glycolysis) 
accumulation in the presence of oxygen, especially under inflammatory conditions (Samuvel 
et al, 2009) Therefore we included assessment of L(+)-lactate, as a possible marker in 
synovial fluid from the affected joints as well as measuring established inflammatory 
biomarker, prostaglandin E2 (PGE2).  
A prerequisite for the use of lactate as a biochemical biomarker was that it should provide 
information about the ongoing inflammation and preferably without interfering with the 
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target. In Paper I we could demonstrate significant decrease of PGE2 in synovial fluid 
following treatment with two COX-inhibitors, naproxen and rofecoxib, despite the drugs 
having limited efficacy on overall joint swelling. We could also demonstrate that L(+)-lactate 
levels were unaffected by COX-inhibitors, indicating that L(+)-lactate can be a useful marker 
of experimentally induced inflammation especially for monitoring the non-cox-inhibitor 
sensitive cascade. Furthermore, lactate may therefore have direct utility as a 
pharmacodynamic marker in drug development for inflammatory joint diseases. 
 
In Paper II the main purpose was to identify possible soluble biochemical biomarkers from a 
translational viewpoint, meaning that we compared findings/biomarkers from established 
animal models with those from patients with osteoarthritis.  
The FCA model has mainly been used to study the pathology and/or symptoms of 
rheumatoid arthritis, such as joint pain, while the MIA model is used for studies of the 
pathology of osteoarthritis (Muir et al, 1982, Guzman et al 2003, Bendele et al, 2001). The 
MIA model is not totally accepted as a model of human OA pathology, since some regard 
this model as mainly exhibiting painful behavior, but the model primarily induces cartilage 
degradation, osteophyte formation and mild synovitis, and thus reflects many of the 
hallmarks of OA.   
 
Synovial fluid from patients can be taken in two ways, either from outpatient clinic 
volunteers who are undergoing drug treatment, or taken from patients in the late stage of 
disease during joint replacement surgery. Results from patients in the former group, 
presented in Paper II, may differ depending on the sampling technique and may not be 
directly comparable with results from patients in the latter group. All human subjects in our 
study had ongoing drug treatment  (NSAIDs or prednisolone), which potentially could 
influence the synthesis of cytokines such as IL-6, TNF and IL-8 (Gallelli et al 2013, Youssef et 
al, 1997, Young et al, 2001). 
 
In synovial fluids, all tested biomarkers were observed in the FCA model, but only IL-6, 
KC/GRO, MCP-1 and MIP-3α were increased (not IL-1β and TNF), although at a lower 
magnitude, in the MIA model, suggesting that the underlying pathology in these two models 
is significantly different. Both models also had different systemic inflammatory profiles since 
only IL-6 in MIA serum followed the pattern of IL-6 in synovial fluid, whereas in the FCA 
model IL-6, KC/GRO and MIP-3α levels were all similarly elevated in both matrices. In five of 
the six OA individuals we observed a wide range of levels for all biomarkers, except IL-1β 
and TNF, in either synovial fluid or serum. One individual (donor 1) showed extremely high 
levels of all markers in synovial fluid, but which were not that markedly increased in serum. 
However, one of the aims of this study was to investigate whether markers in blood reflect 
the levels in synovial fluid, which was true for MIP-3α in humans as also seen in the FCA 
model. Nevertheless, we could not observe any significant difference when comparing levels 
of MIP-3α in the OA group with the control group, therefore this chemokine cannot be 
regarded as a biochemical biomarker in OA individuals despite being correlated between 
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serum and synovial fluid. Interestingly, we observed two common findings between the MIA 
model and in humans, namely the lack of IL-1β and TNF in synovial and serum (in five out of 
six patients), and the presence of elevated levels of IL-6 in joint and serum. However, we did 
not find a positive correlation between IL-6 in synovial fluid and serum from the OA 
individuals but as indicated in the MIA model, where serum IL-6 levels followed synovial 
fluid with a lag time, it is possible that the IL-6 levels change over time, implicating different 
states of disease progression.  
 
Elevated levels of IL-1β and TNF have previously been reported mainly in RA patients and 
more recently others have concluded that IL-1β is not consistently elevated in the OA joints 
(Scanzello et al, 2012) On the other hand, reports indicate that IL-1β and TNF in articular 
cells amplify osteoarthritis by inducing the production of several inflammatory biomarkers 
and mediators including IL-6, IL-8 and MCP-1 (Kapoor et al, 2011, Brenner et al, 2004). It 
could also be a question of time, as an example, if IL-1β precedes IL-6, it is possible that the 
phase of IL-1β and TNF involvement had passed the time for detection of these markers 
both in the MIA model and in humans where the disease progression might have advanced 
to a low IL-1β and TNF state. Recently, it has been shown that the limited success with anti-
IL-1 drugs as disease modifying drugs for OA could be explained by the varying degree of IL-
1 involvement in OA pathology (Kopf M et al, 2010, Jotanovic et al, 2012). X. Chevalier 
reported 2009 that anakinra (anti-IL-1) was hypothesized to counter symptoms of pain and 
stiffness or changes in cartilage metabolism that may be related to excess IL-1 or an IL-1–
related effect but, in their study, there were no improvements in knee pain, function, 
stiffness, or cartilage turnover.  
Finally, in Paper II we predicted, due to findings in paper I, that increased levels of L(+)-
lactate would be found in the affected joints and as expected, L(+)-lactate was readily 
detectable, correlating (in most cases) with the levels of cytokines and chemokines and 
thereby also indicating the presence  of invading cells into the joint cavity. Overall, this 
suggests that a general on-going inflammatory process in the joints is being reflected by 
increased levels of L(+)-lactate. 
 
In Paper III one of the main aims was to determine if there were changes in inflammatory 
biomarkers in serum during the time of treatment that could be used as a biomarker that 
indicates an effect of the drug imatinib in rats subjected to spinal cord injury. In addition to 
the classical markers, INF-γ, IL-1β, TNF, IL-6, KC/GRO, IL-2, IL-4, IL-5, IL-10 and IL-13, 
measurable with a 10-plex immunoassay plate (Mesoscale Discovery) we analyzed the MCP-
1 (monocyte chemoattractant protein-1) and MIP-3α (macrophage inflammatory protein). 
Both MIP-3α and MCP-1 are known to have chemotactic properties and are associated with 
macrophages, and as shown in Paper II, both markers could readily be measured in both rat 
and human serum, with or without a challenge. MCP-1 has previously been shown to 
increase in patients with cancer receiving the drug imatinib (Hayashi et al, 2012) , but in 
general, no biomarkers have been explored or used in previous clinical trials with 
treatments for spinal cord injury. In Paper III, we could demonstrate that levels of MCP-1 
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and MIP-3α were significantly increased in serum, from day 1 to day 7 following injury in the 
imatinib group.  These two markers were also elevated similarly in serum from uninjured 
rats that received imatinib and where MIP-3α proved to be more robust (less variation and 
higher significance) as compared to MCP-1. KC/GRO showed a slightly different pattern of 
levels throughout the study, but was significantly increased as well by day 7 following injury 
and treatment.  
These results indicate that we have found a time point (7 days) when the increase of MCP-1, 
MIP-3α and KC/GRO can be usefully monitored as a biomarker of treatment effect, and if 
comparing with levels from day one the SCI individual could be its own control. It is plausible 
that our findings will translate to humans. Finally, it might be useful to use all these three 
biomarkers in combination to evaluate the most robust temporal response and thereby 
distinguish responders from non-responders to imatinib. 
 
In Paper I and II we demonstrate findings regarding several inflammatory biomarkers 
produced as a result of induced inflammation with Freund´s Complete Adjuvant, where 
prostaglandin E2, not only known to be a well-established biomarker for inflammation, is 
also known to promote inflammatory pain by sensitizing afferent nerve endings. It is also 
known that nerve growth factor (NGF) is released following tissue injury and experimental 
data indicates that NGF is important in initiating and maintaining persistent pain associated 
with inflammation. In Paper V we aimed to test whether blockade of NGF, TRPV1 and COX 
activity generated a similar anti-nociceptive profile in rats as previously demonstrated in 
humans (Lane et al, 2010 Spiering et al, 2013). Firstly, we wanted to test whether NGF is 
released into the synovial fluid in the FCA model. No specific rat NGF kit is available 
commercially so for this we developed an immunoassay using electro chemiluminescence 
technology. We could successfully detect NGF in rat joints fluid subsequent to induction 
with Freund`s complete adjuvant. NGF in synovial fluid following saline injection were 
unchanged from one day to 10 days whereas induction with FCA significantly increased the 
levels of NGF suggesting that this model can be used to demonstrate efficacy of several 
treatments related to increased levels of NGF including anti-NGF treatment itself.  
 
 
Methodology 
 
Normally a validation of kits is performed in advance of analysis of study samples, and in 
some cases the validation has to be extended with more dedicated stability tests due to the 
expectations of the study or due to limitations in study samples such as age, volume and 
frequent sample handling.It is important to evaluate which matrix, serum or plasma, is most 
appropriate to use for detection of the biochemical markers especially if they are sensitive 
to clotting factors. In Paper II we found differential distribution of markers, KC/GRO and 
MCP-1 between serum and EDTA plasma preparations from the same animal, and we also 
observed a similar difference in the distribution of IL-8 (KC/GRO in rats) and MCP-1 between 
serum and EDTA plasma within the same human These findings have made us aware that 
 26 
the right matrix has to be used for any given specific analyte. This finding is of great general 
utility in the field. 
 
In Paper IV all samples had been thawed more than once and levels were therefore 
expected to be low or maybe not even detectable at all. Only two markers, IL-6 and IL-8, 
reached levels above detection limit (the lower definition of sensitivity). If too many sample 
levels are below limit of quantification but above limit of detection it is important to check 
that no other parameters are affecting the levels, such as several freeze-thaw cycles which is 
known to affect the concentration of cytokines. Such an effect must be checked with 
stability tests for the marker of interest using a more sensitive assay. Our choice was an IL-6 
single-plex in contrast to the 10-plex that was used for the original study samples. However, 
no significant difference in IL-6 concentration was observed in cerebro spinal fluid (CSF) 
samples that had been thawed once or twice, and levels were found to be above the 
detection limit in all samples. We conclude that IL-6 in CSF is not sensitive to this number of 
freezing /thawing cycles. 
 
Lastly, critical aspects for the development of immuno assays are the choice of and use 
conditions for capture and detection antibodies. In Paper V we reported the successful 
development of an assay for the measurement of rat NGF in synovial fluid. The included 
antibodies were tested at several concentrations to find the optimal limit of quantification 
and the lowest possible background values, but were not tested for related proteins. To 
even further improve the assay, it could be tested against other proteins to assure the 
specificity for NGF, but the antibodies used are stated to be specific due to the 
manufacturer (R&D Systems). 
In conclusion, in experimental trials of inflammation there is a need for stable and reliable 
biochemical biomarkers that reflect the biological process and specific treatment effects. 
While we found increased levels of inflammatory biomarkers in joint fluid and blood, we 
found difficulties to identify a single systemic biochemical biomarker to illustrate an ongoing 
local inflammatory process in osteoarthritis. Furthermore, we conclude that inflammatory 
biomarkers, in either joint fluid or serum, could be used to evaluate the efficacy of specific 
drugs. Lastly, we found that some biomarkers have different ranges and dynamics in serum 
and plasma in both the animal models and in humans. We conclude that the usage of 
biochemical biomarkers has wide application, and may be used as a complementary tool to 
other readouts, such as symptoms, for the analysis of inflammatory conditions. 
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7  GENERAL CONCLUSIONS 
Biological aspects 
 
Paper I 
L(+)-lactate can be used as an additional biochemical biomarker of inflammatory 
processes in rats. 
 Both biomarkers, L(+)-lactate and PGE2  increased following  inflammation challenges. 
 Treatment with COX-inhibitors resulted in a significant decrease of PGE2 whilst L(+)-lactate was 
unaffected. 
 Inhibition of PGE2 synthesis resulted in only partial acute anti-inflammatory properties. 
Paper II 
Elevated levels of inflammatory biomarkers are present in the arthritic joints in rat and 
human.  
  The presence of pro-inflammatory markers in the joint fluids indicates ongoing inflammation.  
  L(+)-lactate might be used as a biomarker for  ongoing general inflammation in the human OA 
joint.  
Biomarkers in blood reflected the ongoing inflammation in joints in osteoarthritic 
individuals and in arthritis models but no specific translational biomarker between the OA 
patients and animal models was found. 
 More biochemical biomarker work needs to be done regarding patients with osteoarthritis. 
 There is a need to identify a credible translational rodent model of osteoarthritis. 
Paper III 
MIP-3α and MCP-1 in serum can be used as biomarkers following imatinib treatment. 
 Chemokine levels in serum on an individual basis may serve as candidate biomarkers for  the 
effect of imatinib. 
 Chemokine levels in serum might also be used to stratify patients, such as to distinguish 
imatinib responders from non-responders. 
Paper V 
Nerve growth factor (NGF) is a product of FCA induced inflammation in rats. 
 A successful method for the evaluation of rat NGF was developed. 
 FCA induced monoarthritis might be a relevant model when testing drugs targeting the 
NGF/TrkA pathway. 
Methodological aspects 
 
Paper II 
The right matrix has to be used for any given specific biomarker. 
 Some biomarkers (MCP-1 and KC/GRO, IL-8) have differential distribution and dynamic range of 
movement in serum and plasma. 
 
Paper IV  
A proper stability test provides information about the possible use old samples. 
 IL-6 in human cerebrospinal fluid can be measured following repeated thaw/freeze cycles 
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8 POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
 
Biokemiska biomarkörer är små komponenter, naturligt förekommande eller experimentellt 
framkallade, som är mätbara i kroppsvätskor och som kan ge information om hur kroppen 
mår. Biomarkörer kan vara ett ”verktyg” för att beskriva sjukdomsprocesser eller för att 
bedöma hur individer svarar på farmakologisk behandling. Fokus i denna avhandling är att 
studera inflammatoriska markörer, så kallade mediatorer, kemokiner och cytokiner som 
lockar immunceller från blodet till platsen för skada och som reglerar förloppet av den 
inflammatoriska processen vid platsen för inflammation, exempelvis en knäled. Vi ville också 
ta reda på om det är möjligt att mäta markörer i blod som speglar inflammationsförloppet i 
en kroppsdel. Dessa biomarkörer mäter man med speciella analyser där antikroppar är den 
viktigaste komponenten. 
I den första studien använde vi två etablerade djurmodeller, Freund's Complete Adjuvant 
(FCA) och karragenan för att skapa, inducera, experimentell inflammation i ankelled hos 
råtta och för att bevisa att inflammationen pågick i leden mättes ledsvullnad. Vi gav djuren 
två cyklooxygenas (COX) hämmare, naproxen och rofecoxib, och kunde påvisa en signifikant 
minskning av prostaglandin E2 (PGE2), som är en produkt av inflammation och så kallad 
mediator, i ledvätska efter behandling trots att drogerna har begränsad effekt på den totala 
ledsvullnaden. L(+)-laktat, som är slutprodukten av sockeromsättningen i cellerna och som 
återspeglar cellaktivitet, kan därför vara en lämplig indikator på experimentella 
inflammatoriska tillstånd. Vi fann att L (+)-laktatnivåer var opåverkade av COX-hämmare i 
denna studie, vilket tyder på att L (+)-laktat kan användas som en biokemisk biomarkör för 
pågående inflammation hos individer under behandling med COX-hämmare. I nästa studie 
mätte vi nivåer av L(+)–laktat, såväl som kemokiner och cytokiner, i ledvätska från patienter 
med artros och från en ytterligare djurmodell, monoiodoacetate (MIA), vilken främst 
inducerar brosknedbrytning, osteofytbildning och lindrig synovit. MIA producerade distinkta 
inflammatoriska biomarkörer i ett bifasiskt mönster men med betydande lägre magnitud 
(nivåer) än FCA modellen, vilket tyder på att den underliggande patologin i dessa två 
modeller är betydligt annorlunda. Som väntat, var L(+)- laktat mätbar i ledvätska i MIA-
modellen och hos människa, som korrelerade med nivåerna av cytokiner och kemokiner 
vilket indikerade närvaro av inflammatoriska celler i leden. Vi observerade även två 
gemensamma fynd mellan MIA modellen och hos människa, närvaron av IL-6 i leden och 
serum samt avsaknaden av IL-1β och TNF i samma matriser. Trots detta fann vi det svårt att 
identifiera en systemisk biokemisk biomarkör som kunde illustrera en pågående lokal 
inflammatorisk process hos patienter med artros. Vi kunde inte heller identifiera en specifik 
translationell (överförbar) biomarkör mellan djurmodeller och individer med artros. 
I den tredje studien, hos råttor som utsatts för ryggmärgsskada, var de viktigaste resultaten 
förändringar av inflammatoriska biomarkörer i serum under tiden för behandling med 
läkemedlet imatinib, en tyrosinkinashämmare. Även om serumnivåer av de kemotaktiska 
markörerna MCP-1 och MIP-3α var förhöjda vid dag 1 efter skada eller simulerad skada, 
förblev nivåerna likartade eller lägre under hela studien upp till 7 dagar. MCP-1 och MIP-3α 
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var dock ytterligare förhöjt 7 dagar efter inducerad skada i imatinibgruppen. Det är troligt 
att våra resultat kommer att kunna översättas till människa och att den ryggmärgsskadade 
individen kan vara sin egen kontroll vid jämförelse med värden vid skadans början. 
En ytterligare faktor, förutom de som tidigare nämnts som frisätts efter vävnadsskada är 
nervtillväxtfaktorer (NGF). Flera studier har visat att under den inflammatoriska processen 
finns det  en lokal ökning av NGF vid inflammationsstället och NGF kan vara relaterad till 
uppkomst och upprätthållande av inflammmatorisk smärta. Vi behövde därför veta om NGF 
var mätbart i ledvätska hos djur med FCA inducerad inflammation. Vanligtvis finns det 
”analyskit” kommersiellt tillgängliga för de flesta analyser men i detta fall fanns endast de 
enskilda ingående kemikalerna att köpa, vilket betyder att forskaren måste utveckla/skapa 
en analysmetod för dedikerad frågeställning. I den sista studien rapporterade vi om en 
framgångsrik utveckling av en analysmetod för mätning av råttNGF i ledvätska hos råttor 
som exponerats för FCA och som i sin tur möjliggjorde fortsatta studier där förekomsten av 
NGF i ledvätska var viktig information. 
En slutsats från dessa studier är att biokemiska markörer har ett brett användningsområde, 
till exempel för att användas som kompletterande verktyg till klinisk diagnostik, för 
identifiering av inflammatoriska tillstånd. 
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